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Streptococcus pyogenes (group A streptococcus, GAS)
is an important Gram-positive human pathogen,
which causes mild to severe diseases, including
tonsillitis, pharyngitis, cellulitis, scarlet fever, rheu-
matic fever, necrotizing fasciitis, and streptococcal
toxic shock syndrome (STSS).1,2 In Taiwan, the
most common clinical manifestation of GAS infec-
tion is skin and soft tissue infection.3 The invasive
GAS infections, such as bacteremia and STSS, are
associated with a high mortality rate (25% for
bacteremia and 66.7% for STSS).3 In addition, GAS
is one of the major pathogens that causes child-
hood bacterial pharyngitis in Taiwan.4
Many virulence factors of GAS have been
identified, including bacterial surface proteins,
hyaluronic acid capsule, secreted streptolysins,
hyaluronidase, streptokinase, DNase, and many
streptococcal pyrogenic exotoxins.5 Streptococcal
pyrogenic exotoxin B (SpeB) is one of the most
important virulence factors of GAS. SpeB is the
predominant extracellular protein in streptococcal
culture supernatant. It is secreted as a 42-kDa zy-
mogen and autocatalyzed into an active 28-kDa
cysteine protease.6,7 The conversion of the zymo-
gen form of SpeB is a stepwise process that involves
at least eight intermediates, with a combination of
cis- and trans-processing.6 Chen et al have specu-
lated that the 28-kDa active form of SpeB is im-
portant for converting the 42-kDa zymogen to
28-kDa SpeB under physiological conditions.6
SpeB is a super-active protease with endopepti-
dase activity and has substrate specificity similar
to that of the papain family proteases.8 SpeB cleaves
or degrades host extracellular matrix, immuno-
globulins, complement components, and even
GAS surface adhesins (M protein and protein F1),
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C5a peptidase, and several secreted proteins
(Table).6–35 Destruction of host defense system
proteins and cleavage of GAS surface proteins
may help the bacterium to escape immune clear-
ance, invade the deeper tissues, and disseminate
from the primary infection site. Furthermore, SpeB
is also considered to be the major antigen involved
in the pathogenesis of acute post-streptococcal
glomerulonephritis (APSGN).36–40
Natural Sequence Variations
The speB gene is located on the bacterial chromo-
somal DNA and is present in all analyzed GAS
strains. The nucleotide sequence of the speB gene
is highly conserved. It is believed that the speB gene
sequence variation is due to accumulation of point
mutations.15 In addition, the sequence variation
among GAS strains has no apparent association
with different clinical symptoms, geographic lo-
cations, or time periods.15 Although all GAS strains
have the speB gene, about 25–40% of analyzed
strains express little or no SpeB protein.41,42 Inter-
estingly, Kansal et al43 and Shiseki et al44 have
shown that more STSS-derived strains have little
or no SpeB expression compared with noninvasive
strains. However, the molecular mechanism and
the biological significance of the SpeB non-secretor
strains are still unknown.
The SpeB protein can be divided into three
major forms, mSpeB1, mSpeB2 and mSpeB3, 
Table. Host and bacterial proteins cleaved by SpeB
Before SpeB cleavage After SpeB cleavage Potential effects References
Host proteins
Interleukin-1β precursor Active interleukin-1β Induce inflammation 14
Pro-matrix metalloprotease Active MMP (2, 9) Enhance tissue damage and bacterial invasion 21, 22
(pro-MMP 2, 9)
Fibronectin Fragmented Participate in bacterial colonization and invasive 15
infection
Vitronectin Degraded Enhance tissue damage 15
Kininogen Bradykinin Increase vascular permeability; induce fever and pain 23
Immunoglobulin Cleavage into Fc and Inhibit immunoglobulin-mediated opsonophagocytosis 12, 24, 25
(IgA, IgM, IgD, IgE, IgG) Fab fragments
C3b Degraded Escape phagocytosis 26
Plasminogen Degraded Reduce plasmin activity on GAS surface 27
Bacterial proteins
Zymogen form of SpeB Active SpeB Degrade or cleavage of bacterial and host proteins 6–8, 28
M protein Remove 24 amino acids Alter immunoglobulin binding properties; 10, 29, 30
from N-terminus; release promote bacterial dissemination
from bacterial surface
Protein F1 Degraded Reduce bacterial internalization 11, 17
EndoS Degraded Lost IgG glycan-hydrolyzing activity 9
SmeZ Degraded Abolish immune stimulatory activity 31
Fba Degraded Inhibit binding of FH and FHL-1 32
C5a peptidase Release from bacterial Degrade chemotactic complement factor C5a 10, 33, 34
surface
Streptokinase Degraded Unknown 13, 19
Protein H Release from bacterial Promote bacterial dissemination 10
surface
Sda1 Degraded Decrease neutrophil extracellular trap clearance 35
according to the primary amino acid sequence
(mSpeB1, S208 and A317; mSpeB2, G308 and
A317; mSpeB3, S308 and S317).45 The protease
activity of these three variants is similar, however,
only mSpeB2 has the human integrin (αvβ3 and
αIIbβ3) binding domain, the arginine–glycine–
aspartic acid (RGD) domain. Although the role of
the mSpeB2 RGD domain in pathogenesis is not
established, Stockbauer et al have proposed that the
RGD motif of SpeB may participate in: (1) bac-
terial adherence to the host cell surface; (2) inhi-
bition of platelet aggregation; and (3) enhancing
its degradation efficiency by concentrating the SpeB
at local infection sites.45 In summary, although
sequence variations (speB gene and SpeB protein)
are found among different strains, the significance
of these variations is not well established.
Disease Severity
In clinical epidemiology surveillance, the associ-
ation of SpeB expression with disease severity in
GAS infection is still controversial. The M1 type,
the most dominant serotype of GAS infection, 
is significantly associated with higher protease
expression.42 In addition, high-level protease pro-
duction is associated with severe symptoms in-
cluding STSS, soft tissue necrosis and mortality.42,46
Although these studies have suggested that SpeB
is an important risk factor in severe GAS infec-
tion, the opposite results have been shown by
other studies. Shiseki et al have reported that STSS-
derived strains express lower levels of cysteine
protease than do scarlet-fever-derived strains.44
Similarly, an inverse relationship between disease
severity and SpeB expression has been found in
M1 isolates. This suggests that the decreased SpeB
expression may help bacteria to maintain an intact
surface M1 protein structure, which aids in resist-
ing immune clearance.43 These controversial re-
sults suggest that the severity of GAS infection does
not depend on a particular virulence factor like
SpeB. The interaction between bacterial virulence
and host factors may determine the final outcome
of infection.
Bacterial Internalization
Although GAS is considered an extracellular
pathogen, recent studies have shown that GAS
can internalize into epithelial cells. Strains iso-
lated from bacteremia patients have shown inter-
nalization activity equal to that of intracellular
pathogens such as Salmonella spp. and Listeria
monocytogenes.47 In clinical studies, intracellular
GAS has been detected inside the epithelial cells
in biopsies from GAS-infected patients biopsies or
tonsils from asymptomatic carriers.48,49 Osterlund
et al have reported that GAS in epithelial cells
was detected in 36% of asymptomatic carriers and
in 93% of GAS-infected tonsillitis patients.48,49 In
addition, GAS has also been found inside human
macrophage and macrophage-like cells collected
from acute invasive diseases or asymptomatic GAS
carriers.49,50 In cell culture models, after eradica-
tion of the extracellular bacteria by antibiotic treat-
ment, GAS can survive inside epithelial cells for
4–7 days.51 When the antibiotics are removed from
the culture medium, viable GAS can externalize
and establish an extracellular infection, which
causes cell death and monolayer damage.51,52
These studies have indicated that GAS can survive
inside epithelial or macrophage-like cells for a
period of time, and externalize to cause recurrent
infections. Intracellular GAS also contributes to
penicillin resistance.53 Penicillin is the first choice
for treatment of GAS infection. Although there is
no evidence to show that the minimum inhibitory
concentration of penicillin for GAS is changing,
the failure rate of bacterial eradication in strepto-
coccal pharyngotonsillitis is 2–38%.51,54 Kaplan
et al have demonstrated that intracellular GAS 
is efficiently eradicated by either erythromycin or
azithromycin, but not by penicillin, cephalosporin
or clindamycin.55 These studies suggest that an
intracellular niche provides a barrier for GAS to
escape killing by penicillin.
However, the role of SpeB in bacterial inter-
nalization is controversial. Tsai et al have shown
that, although the adhesion ability of NZ131
(M49) and its speB isogenic mutant is similar, the
speB mutant exhibits a two- to threefold decrease
SpeB in Streptococcus pyogenes
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in internalization into A-549 human alveolar
carcinoma epithelial cell line.56 In addition, the
internalization activity is increased when cultured
cells are infected by an speB mutant supplement-
ed with purified SpeB protein.56 Chaussee et al 
have further demonstrated that SpeB affects the
fibronectin-mediated internalization pathway.11
The major fibronectin-binding protein of GAS,
protein F1, is efficiently degraded by SpeB. The
degradation of protein F1 reduces bacterial fibro-
nectin binding and internalization activities.17
However, in other studies, inactivation of the speB
gene has increased internalization into HEp-2 and
Chinese hamster ovary cell lines.11,57 These con-
flicting results may be caused by the different GAS
strains and cell lines used in different studies. In
general, it is believed that SpeB alters the bacter-
ial surface proteins to affect the internalization
efficiency, but which proteins, and how these
surface proteins are involved in internalization,
may be strain dependent.
Apoptosis
In addition to being responsible for recurrent in-
fection and antibiotic resistance, internalized GAS
also causes epithelial cell apoptosis. About 20%
of A-549 cells and 11–13% of HEp-2 cells undergo
apoptosis after GAS infection.58 GAS internaliza-
tion is required for inducing epithelial cell apop-
tosis. Therefore, the virulence factors responsible
for GAS internalization, such as protein F1 and
SpeB, are considered to have a critical role in
apoptosis.58,59 Recently, SpeB protease activity has
been shown to be required for inducing apoptosis
of cultured cells.60 Mitochondrial dysfunction and
upregulation of calcium-binding protein genes
have been observed in SpeB-induced apoptotic
cells.61 In addition, the activation of both intrinsic
and extrinsic caspase pathways has been observed,
which indicates that SpeB may cause mitochon-
drial dysfunction and trigger apoptosis via the 
receptor-binding pathway.61,62 Tsai et al found that
the 28-kDa SpeB protease mutant protein induces
apoptosis effectively, unless cells are pretreated
with active SpeB protein, which suggests that SpeB-
induced apoptosis is mediated through a receptor-
like mechanism.62 Further studies have identified
integrin αvβ3 as the cell receptor of SpeB.60
Mutation in the integrin binding site of SpeB (the
RGD motif) partially decreases its induction of
apoptosis. In addition, binding of Fas to SpeB has
also been demonstrated.60 Fas-Fas ligand binding
is an important pathway for inducing apoptosis.
Tsai et al found that anti-Fas antibody inhibits
apoptosis induced by SpeB or the RGD motif mu-
tant SpeB, which suggests that SpeB also induces
apoptosis through the Fas-mediated apoptotic
signaling pathway.60 SpeB protein is internalized
into epithelial cells via lysosome- and clathrin-
dependent pathways.63 However, internalized
SpeB is degraded within 60 minutes after its con-
tact with cells, which suggests that internalized
SpeB may have no role in caspase activation.63
Purified SpeB protein also induces human
monocyte-like U937 cells and human polymor-
phonuclear (PMN) cells to undergo apopto-
sis.64–66 The cysteine protease activity of SpeB is
important for triggering apoptosis in these cells.65
In addition, the interleukin-1β converting en-
zyme family protease and Fas-mediated apoptosis
pathway might be associated with the SpeB-
induced apoptosis pathway, however, the mecha-
nism is not clear.65,66 Inducing apoptosis of
phagocytic cells may contribute to evading 
immune clearance.
Evasion of Immune Clearance
SpeB is known to be an important factor in re-
sisting clearance by phagocytosis and survival in
host blood. In a mouse model, the speB mutant
was eliminated effectively from the peritoneum
after infection, but the wild-type strain was
not.67 In addition, the purified SpeB protein re-
duces U937 cell phagocytic activity and human
PMN cell metabolic activity by causing mitochon-
drial damage.65,68 While it directly causes PMN
cell damage, SpeB also cleaves antibody and com-
plement components to escape antibody- and
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complement-mediated phagocytosis. Collin et al
showed that SpeB cleaves IgG into Fc and Fab
fragments.24 Eriksson and Norgren showed that
SpeB cleaves antigen-bound (Fab region-bound)
IgG efficiently, but not Fc region-bound IgG.12
This study indicates that SpeB recognizes and
cleaves antigen-bound IgG to avoid Fcγ-receptor-
mediated phagocytosis, and leaves nonspecific
IgG on the bacterial surface as a host-like mask.
In addition, recent studies have shown that several
complement components are digested by SpeB.
Complement component C3 is the central com-
ponent of the complement activation cascade. It
is digested by C3 convertase to generate C3b. C3b
binds to pathogen surfaces to facilitate phagocy-
tosis, initiate the alternative complement pathway,
and amplify the effects of the classical pathway.
Kuo et al found that SpeB cleaves serum C3, which
impairs C3 fragment opsonization on the surface
of GAS.16 Terao et al showed that either recom-
binant SpeB protein or wild-type GAS strains
rapidly degrade C3b.26 In addition, SpeB releases
the C5a peptidase from the GAS surface, to inac-
tivate the leukocyte chemotaxis activity of C5a.10
Properdin, a positive regulator of complement ac-
tivation, is also degraded by SpeB.69 These studies
indicate that SpeB degrades important comple-
ment components, which impairs the comple-
ment activation pathway and allows GAS to
evade opsonophagocytosis.
Animal Models
Although several lines of evidence indicate that
SpeB is an important virulence factor of GAS, 
the results from mouse infection models are in
conflict. Mice infected by M1, M3 and M49 speB
mutants, through air pouch or intraperitoneal
challenge, showed less mortality compared with
that of the wild-type strains.70,71 Supplementa-
tion with recombinant SpeB protein during speB
mutant infection in the air pouch infection model
increased mouse mortality.70 The speB mutant
also showed a decrease in bacteremia and dis-
semination to organs during infection.67,72 When
mice were infected subcutaneously, the speB
mutant caused significantly smaller abscesses than
those with the wild-type strain.73 Finally, SpeB-
immunized mice were protected from lethal wild-
type strain challenge.70 However, conflicting results
have been observed in other studies. Ashbaugh
and Wessels showed that the virulence of two speB
mutants derived from the same parental strain
was different.74 Only one speB mutant showed
less virulence for mice after intraperitoneal infec-
tion.74 When compared with the wild-type strain,
this speB mutant lost SpeB expression and de-
creased expression of its hyaluronic acid capsule.
The other speB mutant, which had equal capsule
expression to the wild-type strain, showed no
significant decrease in virulence for mice, after
intraperitoneal or subcutaneous infection. Saouda
et al showed that injection of SpeB protein alone
into the skin air sac did not cause significant tis-
sue damage.75 Tissue necrosis was increased and
accelerated by infection of mice by SpeB in com-
bination with GAS (wild-type strain or speB mu-
tant). Both studies have indicated that one or
more bacterial components, other than SpeB, are
critical factors that cause severe GAS infection in
mouse models.
Phase-shift of SpeB Expression
Passage of GAS in either human blood or mice
induces alteration of bacterial colony morphology
and the pattern of expression of virulence genes.
Kazmi et al showed that upregulation of SpeA ex-
pression and downregulation of SpeB expression
were observed after GAS passage in a mouse in-
fection chamber model.76 Raeder et al demon-
strated that large- and small-colony variants are
present after passage in human blood or mice.77
The large-colony variants are SpeB negative, but the
small-colony variants are SpeB positive. Because
SpeB degrades many bacterial proteins, downreg-
ulation of SpeB expression in vivo may help bacte-
ria establish successful infection by retaining their
surface and secreted proteins.78 Therefore, SpeB
negative strains are considered to be the invasive
SpeB in Streptococcus pyogenes
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strains. Engleberg et al found that the large-colony
variants (SpeB-negative strains) have a sponta-
neous mutation of the covR/S gene.79 CovR/S, the
best-characterized two-component regulatory
system of GAS, is an important global regulator
in GAS.80,81 The strains with the covR or covS gene
mutations show an increase in SpeA expression
and a decrease in SpeB expression.82 In addition,
complementation of covR/S expression with a
plasmid in SpeB-negative strains can restore SpeB
expression.82 These experiments have demon-
strated that the covR or covS gene mutations are
associated with loss of SpeB expression. In addi-
tion, the bacteriophage-encoded DNase (sda1) is
essential for the phase-shift of SpeB expression
(from SpeB-positive to -negative). Sda1 protects
GAS against neutrophil clearance by degrading the
neutrophil extracellular traps.35 Abolition of SpeB
expression may prevent DNase degradation, thus
increasing the neutrophil resistance of GAS. There-
fore, it is hypothesized that the sda1 gene provides
evolutionary selection pressure for switching SpeB
expression during in vivo infection.35
SpeB and APSGN
GAS also causes non-suppurative sequelae such
as rheumatic fever and APSGN. Rheumatic fever
is a complication of throat infection and is most
common among children between 5 and 15 years
old. The clinical symptoms include multiple
joint migratory arthritis, carditis, and rheumatic
heart disease.1,2 APSGN is an immune-complex-
mediated renal disease, which is strongly associated
with GAS infection.37 These diseases are caused
by autoantibody-mediated immune-complex
pathogenesis after GAS infection.38 The SpeB pro-
tein (zymogen and mature form) and anti-SpeB
antibody are considered to be involved in APSGN
pathogenesis.36,37,40 Although several GAS anti-
gens, included streptokinase, glyceraldehyde-3-
phosphate dehydrogenase, and SpeB (zymogen
and mature form) are considered to be involved
in APSGN pathogenesis, recent studies have shown
that increased anti-SpeB antibody titer and SpeB
protein deposition in kidney biopsies are highly
correlated with APSGN, which suggests an impor-
tant role of SpeB in APSGN pathogenesis.36,37,39,40
In a SpeB-hyperimmunized mouse model, im-
munoglobulin deposition, complement activation
and leukocyte infiltration were found in mouse
glomeruli. Furthermore, an anti-SpeB monoclonal
antibody was shown to be cross-reactive with kid-
ney endothelial cells and caused kidney injury.38
These studies suggest that SpeB is an important
antigen and anti-SpeB antibody is involved in
APSGN pathogenesis.
Conclusion
Although many lines of evidence show that SpeB
plays an important role in GAS pathogenesis,
some reports indicate that SpeB is not the major
virulence determinant in either in vitro or in vivo
models. These conflicting results may be due to
the different bacterial strains or different infec-
tion models used. In our opinion, the strain-
strain diversity among GAS may be the major
reason for these discrepancies. CovR/S, the most
important two-component regulatory system
(controlling ∼15% of gene expression in GAS), is
considered to be a negative regulator of
SpeB.80,81 However, the covR or covS spontaneous
mutants show the loss of SpeB expression.79,82
Furthermore, in some strains, mutation of covR
does not affect SpeB expression.83,84 These re-
sults indicate that the regulatory network that
controls SpeB expression in different GAS strains
may be different. In addition, the prophages in
GAS genomes also increase diversity among dif-
ferent GAS strains.85,86 Therefore, the diversity
among strains may cause different responses
when bacteria face the same stimulation. The
regulatory network involved in SpeB expression
is not completely understood, even today.
Understanding how SpeB is regulated by GAS
will help us to further elucidate the role of SpeB
during GAS infection.
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